Golden
Synosia Therapeutics

Synosia Therapeutics

A company developing therapies for psychological and neurological illnesses

Synosia Therapeutics is a biotechnology company developing therapies for psychological and neurological illnesses that is headquartered in Basel, Switzerland and was founded in 2006.

Funding

Series A

On March 6, 2006 Synosia Therapeutics completed their series A funding round with $2.5 million in capital from undisclosed investors. 

Venture round

On January 5, 2007 Synosia Therapeutics completed a venture capital round with $32.5 million in funding from Versant Ventures, Novo Holdings, Abingworth, and 5AM Ventures. 

Series B

On January 1, 2009 Synosia Therapeutics completed their series B funding round with $29 million in funding from Investor Growth Capital Limited (lead investor), Aravis Ventures (lead investor), Versant Ventures, Swiss Helvetia Fund, Novo Ventures, Abingworth, and 5AM Ventures. 

Series C

On October 12, 2010 Synosia Therapeutics completed their series C funding round with $30 million in funding from UCB Pharma (lead investor), Versant Ventures, Swiss Halvetia Fund, Novo Holdings, Investor Growth Capital Limited, Aravis Ventures, and 5AM Ventures. 

Timeline

People

Name
Role
Related Golden topics







Further reading

Title
Author
Link
Type
Date

BioTie Therapies Corp. to Acquire CNS Therapeutics Firm Synosia Therapeutics in $121.5M All-Shares Deal

BioSpace

Web



Synosia Therapeutics Raises $30M in Series C Financing

FierceBiotech

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References